OBIO Orchestra BioMed Holdings, Inc. NASDAQ · United States

Orchestra BioMed Holdings (OBIO) news

Orchestra BioMed Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OBIO, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Orchestra BioMed Holdings news

We have not published a story on Orchestra BioMed Holdings yet. When there is news, it will appear here.

Orchestra BioMed Holdings annual financials

Line	FY2025	FY2024
Revenue	$33.5 million	$2.6 million
Research and development	$58.2 million	$42.8 million
Net income (loss)	-$52.7 million	-$61.0 million
Cash from operations	-$49.0 million	-$50.6 million
Cash and equivalents	$34.7 million	$22.3 million
Short-term investments	$71.8 million	$44.6 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $20.5 million, plus short-term investments of $89.5 million, $110.0 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Orchestra BioMed Holdings

What is the ticker symbol of Orchestra BioMed Holdings?

Orchestra BioMed Holdings, Inc. trades under the ticker OBIO on NASDAQ.

Where is Orchestra BioMed Holdings listed?

Orchestra BioMed Holdings, Inc. is listed on NASDAQ.

Which country or territory is Orchestra BioMed Holdings listed under?

Our directory records Orchestra BioMed Holdings, Inc. under United States.

Does aibio.space cover Orchestra BioMed Holdings?

aibio.space lists Orchestra BioMed Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Orchestra BioMed Holdings's revenue last year?

$33.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Orchestra BioMed Holdings profitable?

Orchestra BioMed Holdings, Inc. reported a net loss of $52.7 million for the fiscal year ended Dec 31, 2025, and used $49.0 million of cash in operations, per its annual report to the SEC.

How much does Orchestra BioMed Holdings spend on research and development?

$58.2 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Orchestra BioMed Holdings have?

$110.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

Investor discussion: Orchestra BioMed Holdings

Members talk about Orchestra BioMed Holdings (OBIO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:OBIO on TradingView.

Listing details

Company: Orchestra BioMed Holdings, Inc.
Ticker: OBIO
Listing: NASDAQ
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction